Clinical trial

Effects of Pioglitazone Treatment on Sympathetic Nervous System Function in Metabolic Syndrome Obesity

NCT00408850

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Pioglitazone Normalized identity: pioglitazoneView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention sugar pill Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Effects of Pioglitazone Treatment on Sympathetic Nervous System Function in Metabolic Syndrome Obesity

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2008-11-01

PhasePHASE3

Conditions

Metabolic Syndromeverified · MONDO: abdominal obesity-metabolic syndrome

Interventions

PioglitazoneDRUG · verified · RxNorm: pioglitazone

sugar pillDRUG

Sponsors & collaborators

Baker Heart Research Institutelead sponsor

National Heart Foundation, Australiacollaborator

Mapped research locations

MelbourneVictoria, Australia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00408850 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.